Chronic graft-vs-host disease (cGVHD) is a frequent, heterogeneous, and often life-threatening complication of allogeneic hematopoietic stem cell transplantation. A total of 25% to 50% of all transplant survivors develop cGVHD, and cutaneous manifestations are seen in approximately 75% of these patients. 1 Cutaneous manifestations of cGVHD include skin fibrosis (sclerotic cGVHD), epidermal involvement resembling lichen planus, or a combination of both findings. Alopecia, genital inflammation/ scarring, nail dystrophy, pigmentary changes, ulceration, and poor wound healing are additional features. Associated skin changes range from mild and self-limited to severe, highly distressing, disfiguring, and permanently disabling disease. 2 Treatment of cGVHD is challenging due to the multiorgan nature of the disease, which may include eyes, lungs, liver, muscles/fascia, and gastrointestinal involvement, as well as difficulties assessing disease activity and treatment response.In this issue of JAMA Dermatology, rather than propose another instrument to quantify the extent of cGVHD-related skin disease, Baumrin and colleagues 3 used 2 well-validated patientreported outcome (PRO) measures, the Lee cGVHD Symptom Scale and the Functional Assessment of Cancer Treatment-BMT, to explore the association of these PROs with survival in patients with cutaneous cGVHD. PROs, including selfreported measures of symptom burden, functional status, and health-related quality of life (HRQL), provide valuable insights in understanding the humanistic burden of disease, are associated with improved risk and prognostic stratification, and gauge therapeutic response and tolerability of treatment. [4][5][6] PROs can also be applied in clinical care to identify unmet needs, improve patient-clinician communication, and target services to patients at greatest risk to experience unfavorable outcomes. 7 Multiple PRO measures are available to capture symptom burden, functional status, HRQL, and mental health as well as to evaluate organ-specific issues, such as pruritus, shortness of breath, or nutritional impairment. Both PRO instruments used by Baumrin et al 3 have demonstrated sensitivity to detect multidimensional effects of cutaneous cGVHD. 6 In their multicenter, prospective, longitudinal cohort study, Baumrin et al 3 compared patients with sclerotic and combination-type (epidermal and sclerotic) cutaneous cGVHD over time with those with epidermal disease only in covariateadjusted models. Baumrin et al 3 demonstrated that compared with those with epidermal disease, patients with sclerotic and combination-type cutaneous cGVHD experienced statistically significant and clinically meaningful declines in HRQL and higher levels of skin-related symptom burden (eg, abnormal color, rash, thickening, sores, and itching). More-